Gemcitabine Phosphoramidate as New Anticancer Clinical Candidate

Prof. McGuigan from Cardiff School of Pharmacy, UK along with Prof. Jan Balzarini of Rega Instutute for Medical Research, Belgium have reported an innovative approach to overcome the cancer Resistance mechanism using the pro-tide technology of their’s. They prepared various Nucleotide Phosphoramidates of the known anticancer drug Gemcitabine and were able to find a molecule that was resistant to cytidine deaminase-mediated […]

» Read more

The New Hep C Drug: PSI-7977 to Sofosbuvir

Recently (December 6th, 2013) Sofosbuvir was approved by US FDA for the treatment of Chronic Hepatitis C in combination with Ribavirin for dual therapy and with Ribavirin & Pegylated Interferon triple therapy for treatment-naive patients having HCV genotypes 1 and 4. The drug is being marketed as Sovaldi by Gilead.

» Read more

Co-First Authors & Bibliography

Just saw this in the editorial comment section of the journal Gastroenterology. What they say is that they are going to introduce the highlighting of the co-first authors in case such an article (Where few authors have made equal contribution) is cited in the references section. [important]A note in such cases will follow the references section that states: “Author names in […]

» Read more
1 2 3 4 5 18